Rubric Capital Management LP raised its stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 14.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,292,132 shares of the specialty pharmaceutical company’s stock after purchasing an additional 296,173 shares during the period. Rubric Capital Management LP’s holdings in BioDelivery Sciences International were worth $12,148,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Close Asset Management Ltd increased its position in BioDelivery Sciences International by 1,340.0% during the 1st quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock worth $95,000 after purchasing an additional 16,750 shares in the last quarter. BlackRock Inc. increased its position in BioDelivery Sciences International by 5.0% during the 1st quarter. BlackRock Inc. now owns 1,457,836 shares of the specialty pharmaceutical company’s stock worth $7,726,000 after purchasing an additional 69,539 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new stake in BioDelivery Sciences International during the 1st quarter worth about $1,245,000. Laurion Capital Management LP increased its position in BioDelivery Sciences International by 128.5% during the 1st quarter. Laurion Capital Management LP now owns 573,638 shares of the specialty pharmaceutical company’s stock worth $3,040,000 after purchasing an additional 322,629 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in BioDelivery Sciences International by 69.0% during the 1st quarter. JPMorgan Chase & Co. now owns 726,578 shares of the specialty pharmaceutical company’s stock worth $3,851,000 after purchasing an additional 296,665 shares in the last quarter. Institutional investors own 58.26% of the company’s stock.

BDSI traded up $0.10 during midday trading on Friday, hitting $4.34. The company’s stock had a trading volume of 533,409 shares, compared to its average volume of 955,196. The company has a debt-to-equity ratio of 1.90, a quick ratio of 2.57 and a current ratio of 2.88. BioDelivery Sciences International, Inc. has a 52-week low of $2.31 and a 52-week high of $5.37.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The company had revenue of $19.77 million during the quarter, compared to analysts’ expectations of $19.60 million. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. Research analysts predict that BioDelivery Sciences International, Inc. will post -0.14 EPS for the current fiscal year.

A number of analysts recently commented on the company. Cantor Fitzgerald set a $8.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, March 22nd. BidaskClub upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Thursday, May 9th. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Finally, SunTrust Banks assumed coverage on BioDelivery Sciences International in a research report on Tuesday, March 19th. They set a “buy” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $6.20.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $4.77, for a total value of $38,160.00. Following the completion of the sale, the director now owns 598,254 shares in the company, valued at approximately $2,853,671.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark A. Sirgo sold 9,050 shares of BioDelivery Sciences International stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $5.20, for a total value of $47,060.00. Following the completion of the sale, the director now owns 2,509,005 shares of the company’s stock, valued at approximately $13,046,826. The disclosure for this sale can be found here. Insiders sold a total of 3,855,335 shares of company stock valued at $19,280,285 in the last 90 days. 13.26% of the stock is owned by company insiders.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/biodelivery-sciences-international-inc-bdsi-holdings-boosted-by-rubric-capital-management-lp/3029450.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.